Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $5.13
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $5.13
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) shares gapped up before the market opened on Thursday . The stock had previously closed at $5.13, but opened at $5.33. Aurinia Pharmaceuticals shares last traded at $5.19, with a volume of 8,387 shares traded.
金色医药股份有限公司(纳斯达克代码：AUPH-GET评级)(东京证券交易所代码：AUP)的股票在周四开盘前大幅上涨。该股此前收盘报5.13美元，开盘报5.33美元。Aurinia PharmPharmticals的股票最新报5.19美元，成交量为8,387股。
Analyst Ratings Changes
分析师评级发生变化
A number of analysts have commented on the stock. Royal Bank of Canada cut their price target on shares of Aurinia Pharmaceuticals from $18.00 to $10.00 and set an "outperform" rating for the company in a research note on Friday, November 4th. HC Wainwright cut their price target on shares of Aurinia Pharmaceuticals from $26.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, November 7th. StockNews.com assumed coverage on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 12th. They issued a "hold" rating for the company. Oppenheimer cut shares of Aurinia Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Friday, November 4th. Finally, SVB Leerink cut their price target on shares of Aurinia Pharmaceuticals from $17.00 to $12.00 and set an "outperform" rating for the company in a research note on Friday, November 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Aurinia Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $12.25.
一些分析师对该股发表了评论。11月4日，周五，加拿大皇家银行在一份研究报告中将金色医药的目标价从18.00美元下调至10.00美元，并为该公司设定了“跑赢大盘”的评级。11月7日，HC Wainwright在一份研究报告中将aurinia PharmPharmticals的股票目标价从26.00美元下调至14.00美元，并为该公司设定了“买入”评级。StockNews.com在10月12日星期三的一份研究报告中对aurinia PharmPharmticals的股票进行了报道。他们对该公司的评级为“持有”。奥本海默在11月4日星期五的一份研究报告中将aurinia PharmPharmticals的股票评级从“跑赢大盘”下调至“市场表现”。最后，SVB Leerink在11月4日(星期五)的一份研究报告中将aurinia PharmPharmticals的股票目标价从17.00美元下调至12.00美元，并为该公司设定了“表现优于大盘”的评级。两名股票研究分析师对该股的评级为持有，五名分析师对该股的评级为买入。根据MarketBeat的数据，aurinia PharmPharmticals的共识评级为“中等买入”，共识目标价为12.25美元。
Aurinia Pharmaceuticals Price Performance
金银花药品价格表现
The company has a market capitalization of $724.76 million, a P/E ratio of -6.14 and a beta of 0.82. The company's 50-day moving average price is $6.43 and its two-hundred day moving average price is $8.51.
该公司市值为7.2476亿美元，市盈率为-6.14，贝塔系数为0.82。该公司的50日移动均线价格为6.43美元，200日移动均线价格为8.51美元。
Hedge Funds Weigh In On Aurinia Pharmaceuticals
对冲基金买入Auinia制药公司
About Aurinia Pharmaceuticals
金色制药公司简介
(Get Rating)
(获取评级)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
Auinia制药公司是一家商业阶段的生物制药公司，专注于开发治疗方法并将其商业化，以治疗在美国和国际上未得到满足的医疗需求的各种疾病。该公司提供LUPKYNIS用于治疗成人活动性狼疮性肾炎。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Aurinia Pharmaceuticals (AUPH)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- 免费获取StockNews.com关于金银花制药的研究报告(AUPH)
- 为什么CSL有限公司的股票值得一看
- MarketBeat：回顾一周11/28-12/02
- Okta Inc.庆祝收益节节攀升，但他们能持续这种提振吗？
- 机构正在购买安巴雷拉，你应该吗？
- ZIM能否抵御集装箱航运业的普遍低迷？
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《金色医药日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对aurinia PharmPharmticals和相关公司的最新新闻和分析师评级的每日摘要。